Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (71-80 of 220) with videos related to

Pageof 22
Sort By:
Clinical Advances in Hematology & Oncology : H&O|May 12, 2011
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancerDavid R Spigel, John D Hainsworth, Howard A Burris, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancerDavid R Spigel, John D Hainsworth, John H Barton, et al.
Clinical Breast Cancer|November 26, 2009
Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancerDenise A Yardley, Howard A Burris, Tiffanie Markus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2009
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, John D Zubkus, et al.
The Oncologist|March 11, 2022
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World SettingsEmma G Sturgill, Amanda Misch, Carissa C Jones, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2007
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkDavid R Spigel, John D Hainsworth, Lisa Simons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junctionDavid R Spigel, F Anthony Greco, Anthony A Meluch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2018
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket StudyJohn D Hainsworth, Funda Meric-Bernstam, Charles Swanton, et al.
Cancer Investigation|February 18, 2010
Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortiumJohn D Hainsworth, Anthony A Meluch, Cassie M Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2018
Reply to J.J. Tao et alJohn D Hainsworth, Funda Meric-Bernstam, Charles Swanton, et al.
Pageof 22

Showing results (71-80 of 220) with videos related to

Sort By:
Pageof 22
Clinical Advances in Hematology & Oncology : H&O|May 12, 2011
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancerDavid R Spigel, John D Hainsworth, Howard A Burris, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancerDavid R Spigel, John D Hainsworth, John H Barton, et al.
Clinical Breast Cancer|November 26, 2009
Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancerDenise A Yardley, Howard A Burris, Tiffanie Markus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2009
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, John D Zubkus, et al.
The Oncologist|March 11, 2022
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World SettingsEmma G Sturgill, Amanda Misch, Carissa C Jones, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2007
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkDavid R Spigel, John D Hainsworth, Lisa Simons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junctionDavid R Spigel, F Anthony Greco, Anthony A Meluch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2018
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket StudyJohn D Hainsworth, Funda Meric-Bernstam, Charles Swanton, et al.
Cancer Investigation|February 18, 2010
Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortiumJohn D Hainsworth, Anthony A Meluch, Cassie M Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2018
Reply to J.J. Tao et alJohn D Hainsworth, Funda Meric-Bernstam, Charles Swanton, et al.
Pageof 22